- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00741455
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Allogeneic bone marrow transplantation (BMT) became feasible in the 1960s after elucidation of the Human Leukocyte Antigen (HLA) complex. Since then, the therapy has evolved into an effective treatment for many hematologic disorders. Otherwise incurable malignancies are frequently cured by this approach, with the likelihood of cure ranging from 10% to 85%, depending on the disease and the disease status. The treatment strategy incorporates very large doses of chemotherapy and often radiation to eliminate cancer cells and to immunosuppress the recipient to allow the engraftment of donor cells. Donor cells give rise to hematopoiesis within two to three weeks, rescuing the patient from the effects of high dose therapy. In the ideal situation, immune recovery and recipient-specific tolerance occurs over the following 6-18 months, and the patient is cured of their underlying malignancy, off immunosuppression, with a functionally intact donor-derived immune system. However, complications are common and include fatal organ damage from the effects of high dose chemotherapy, infection, hemorrhage, and, in particular, graft-versus-host disease (GvHD). A realistic estimate of transplant-related mortality in the standard HLA-matched sibling setting is approximately 25%. The risk of treatment-related mortality limits the success and certainly precludes its use in older patients. Thus, new strategies in transplantation are needed.
With the growing understanding that much of the curative potential of allogeneic bone marrow or stem cell transplant (SCT) is from an immune anti-tumor effect of donor cells, known as graft-versus-leukemia (GvL) or graft-versus-tumor (GvT), a new strategy is being employed that shifts the emphasis from high-dose chemo-radiotherapy to donor-derived, immune-mediated anti-tumor therapy. In this approach, patients receive preparative regimens that, while having some anti-tumor activity, are mainly designed to be immunosuppressive enough to allow engraftment of donor stem cells and lymphocytes. Engrafted lymphocytes then mediate a GvL effect; if the GvL effect of the initial transplant is not sufficient, then additional lymphocytes may be infused (achievement of engraftment allows additional lymphocytes to "take" in the recipient without requiring any additional conditioning of the recipient). The lower intensity of the preparative regimen lessens the overall toxicity by minimizing the doses of chemo-radiotherapy. In addition, less intensive preparative regimens may be associated with less GvHD, as much evidence suggests that high-dose therapy contributes to the syndrome of GvHD by causing tissue damage, leading to a cytokine milieu which enhances activation of graft-versus-host (GvH) effector cells. Thus, such an approach may allow the safer use of allogeneic transplants in standard populations and may allow extension of allogeneic transplantation to patients who could not receive standard (myeloablative) transplants because of age or co-morbidities. This protocol investigates a non-myeloablative transplant approach, using fludarabine and cyclophosphamide, to allow engraftment of allogeneic cells, which may then mediate anti-tumor effects.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age: 18-75 years
Diseases
Chronic myelogenous leukemia (CML)
- First chronic phase or later
- Accelerated phase
Acute myelogenous or lymphoblastic leukemia (AML or ALL)
- Second or subsequent remission
- Patients who have failed an autologous PBSC transplant
- First remission with poor risk features, including, but not limited to: For AML- complex chromosome karyotype, abnormalities of chromosome 5 or 7, 12p-, 13+, 8+, t(9;22), t(11;23) For ALL- t(9;22), t(4;11), t(1;19), myeloid antigen coexpression
- Myelodysplastic syndrome (MDS)
- Multiple myeloma - high risk myeloma (poor responders, relapse after autologous PBSCT, chromosome 13 abnormalities)
Hodgkin's disease
- Primary refractory disease
- Relapsed disease (first relapse or later)
- Patients who have failed an autologous PBSC transplant
Non-Hodgkin's lymphoma Low grade (by Working Formulation)
- Relapsed, progressive disease after initial chemotherapy
- Primary refractory disease or failure to respond (>PR) to initial chemotherapy
- Patients who have failed an autologous PBSC transplant Intermediate grade (by Working Formulation)
- Relapsed disease
- Primary refractory disease or failure to respond (>PR) to initial chemo
- Mantle cell lymphoma
- Patients who have failed an autologous PBSC transplant
Chronic lymphocytic leukemia (CLL)
- Patients newly diagnosed with poor prognostic factors, including CD38 expression, Chromosome 11 or 17 abn
- T-CLL/PLL
- Relapsed or progressive disease, or refractory after Fludarabine
- Patients who have failed an autologous PBSC transplant
- Donor Availability: Six of six matched HLA A, B and DR identical sibling (or parent or child) or 5/6 related donor with single mismatch at Class I antigen (A or B)
- Karnofsky performance status of >70%
- Serum bilirubin <2x upper limit of normal; transaminases <3x normal (unless due to disease)
- 24 hr urine creatinine clearance of >40 ml/min.
- DLCO >50% predicted
- Left ventricular ejection fraction >35%
- No active infection
- Non-pregnant female
- Signed informed consent
- No major organ dysfunction or psychological problems that preclude compliance and completion of the clinical trial.
Exclusion Criteria
- Major organ dysfunction
- Pregnant or lactating female
- Active infection
- Psychological problems that preclude compliance and completion of the clinical trial
- Any other condition, that in the judgement of the investigator, affects participant safety or overall participation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Study Treatment
Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
|
Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient. Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later. Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.
Andere Namen:
10 mcg/kg/day on days 5, 6, and 7
25 mg/m2/d IV over 30 minutes on days -6 to -2
1 g/m2/d IV on days -3 and -2
used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Successful Bone Marrow Engraftment
Zeitfenster: Within 30 days of bone marrow transplant
|
Rates of successful engraftment.
|
Within 30 days of bone marrow transplant
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants Who Achieve Complete Donor Chimerism
Zeitfenster: Post-transplant days +30, +60, +100, +180 and +365
|
Complete donor chimerism
|
Post-transplant days +30, +60, +100, +180 and +365
|
Number of Participants Who Experienced Graft-Versus-Host-Disease
Zeitfenster: Post-transplant procedure through death
|
Collect the number of incidents of acute and chronic graft-versus-host disease
|
Post-transplant procedure through death
|
Overall Survival Measured in Participants
Zeitfenster: Up to 15 Years Post-Transplant
|
Mortality rates in subjects after successful completion of a bone marrow transplant
|
Up to 15 Years Post-Transplant
|
Collection of Adverse Events
Zeitfenster: Until the 6th Bone Marrow Transplant performed in subjects on study
|
Determine the level of toxicity experienced by subjects who receive protocol treatment and bone marrow transplant
|
Until the 6th Bone Marrow Transplant performed in subjects on study
|
Assess Disease Response
Zeitfenster: Post-transplant procedure through death
|
Review and assess the tumor response rate
|
Post-transplant procedure through death
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: John M Hill, MD, Dartmouth-Hitchcock Medical Center
- Hauptermittler: Kenneth R Meehan, MD, Dartmouth-Hitchcock Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Hämatologische Erkrankungen
- Neubildungen
- Hämatologische Neubildungen
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Antirheumatika
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Dermatologische Wirkstoffe
- Antimykotika
- Reproduktionskontrollmittel
- Abtreibungsmittel, nichtsteroidal
- Abtreibungsmittel
- Folsäure-Antagonisten
- Calcineurin-Inhibitoren
- Cyclophosphamid
- Fludarabin
- Methotrexat
- Cyclosporin
- Cyclosporine
Andere Studien-ID-Nummern
- D0345
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Stem Cell Transplant
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Noch keine RekrutierungDepression | Lebensqualität | Nierenerkrankung im Endstadium | Behinderung körperlichVereinigte Staaten
-
StemMedical A/SNoch keine Rekrutierung
-
Oregon Research Behavioral Intervention Strategies...National Institute on Minority Health and Health Disparities (NIMHD)AbgeschlossenSprachentwicklungVereinigte Staaten
-
University Health Network, TorontoAbgeschlossen
-
Immunis, Inc.RekrutierungMuskelatrophieVereinigte Staaten
-
Kessler FoundationRekrutierungMultiple SkleroseVereinigte Staaten
-
Region SkaneLund University; Cambridge University Hospitals NHS Foundation Trust; University...RekrutierungParkinson KrankheitSchweden, Vereinigtes Königreich
-
Oregon Research Behavioral Intervention Strategies...Rekrutierung
-
Signature OrthopaedicsThe Cleveland ClinicRekrutierungHüftersatzVereinigte Staaten
-
William Beaumont HospitalsStryker NordicRekrutierungVerletzungen der Rotatorenmanschette | Arthritis-SchulterVereinigte Staaten